An insilico analysis: three upregulated microRNAs as potential diagnostic biomarkers of Papillary Thyroid Carcinoma (PTC).

IF 2.2 Q3 ONCOLOGY
Maharani Putri Hermawan, Sari Eka Pratiwi, Ridha Ulfah, Eko Rustianto Suhardiman, Mahyarudin Mahyarudin
{"title":"An insilico analysis: three upregulated microRNAs as potential diagnostic biomarkers of Papillary Thyroid Carcinoma (PTC).","authors":"Maharani Putri Hermawan, Sari Eka Pratiwi, Ridha Ulfah, Eko Rustianto Suhardiman, Mahyarudin Mahyarudin","doi":"10.1186/s43046-026-00350-1","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: Papillary thyroid carcinoma (PTC) represents the most prevalent subtype of thyroid cancer. Accumulating evidence indicates that specific microRNAs are consistently dysregulated in PTC and may hold value as biomarker candidates. Accordingly, this study aims to prioritize consistently upregulated microRNAs associated with PTC using an integrative in silico analysis of publicly available datasets. METHODS: This study conducted a comprehensive analysis of miRNA expression patterns using datasets available through A Database of Differentially Expressed miRNAs in Human Cancers (dbDEMC). The dataset was then processed through a data mining approach with a cutoff of P-value < 0.05 and log2FC > 1.5 to identify miRNAs that were significantly and consistently upregulated in the datasets. The target genes are predicted through miRDIP, miRTarBase, miRPathDB, and GEPIA2. Gene ontology and pathway enrichment analysis were performed in ShinyGO and EnrichR. To assess the diagnostic ability of the three miRNAs, CancerMIRNome is used to identify the ROC curve analysis results of each miRNA. RESULTS: This exploratory in silico analysis identified 85 differentially expressed miRNAs in PTC, with hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p consistently upregulated across datasets. Functional enrichment and TCGA-based ROC analyses suggest that these miRNAs may have biological and discriminatory relevance in PTC. However, these findings are hypothesis-generating and require further experimental and clinical validation before any diagnostic application can be considered. CONCLUSION: In summary, our study identified the potential of hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p as potential diagnostic biomarkers of PTC. </p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"38 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313286/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-026-00350-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) represents the most prevalent subtype of thyroid cancer. Accumulating evidence indicates that specific microRNAs are consistently dysregulated in PTC and may hold value as biomarker candidates. Accordingly, this study aims to prioritize consistently upregulated microRNAs associated with PTC using an integrative in silico analysis of publicly available datasets. METHODS: This study conducted a comprehensive analysis of miRNA expression patterns using datasets available through A Database of Differentially Expressed miRNAs in Human Cancers (dbDEMC). The dataset was then processed through a data mining approach with a cutoff of P-value < 0.05 and log2FC > 1.5 to identify miRNAs that were significantly and consistently upregulated in the datasets. The target genes are predicted through miRDIP, miRTarBase, miRPathDB, and GEPIA2. Gene ontology and pathway enrichment analysis were performed in ShinyGO and EnrichR. To assess the diagnostic ability of the three miRNAs, CancerMIRNome is used to identify the ROC curve analysis results of each miRNA. RESULTS: This exploratory in silico analysis identified 85 differentially expressed miRNAs in PTC, with hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p consistently upregulated across datasets. Functional enrichment and TCGA-based ROC analyses suggest that these miRNAs may have biological and discriminatory relevance in PTC. However, these findings are hypothesis-generating and require further experimental and clinical validation before any diagnostic application can be considered. CONCLUSION: In summary, our study identified the potential of hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p as potential diagnostic biomarkers of PTC.

计算机分析:三个上调的microrna作为甲状腺乳头状癌(PTC)的潜在诊断生物标志物。
背景:甲状腺乳头状癌(PTC)是最常见的甲状腺癌亚型。越来越多的证据表明,特定的microrna在PTC中持续失调,可能作为生物标志物候选者具有价值。因此,本研究旨在利用对公开可用数据集的集成计算机分析,优先考虑与PTC相关的持续上调的microrna。方法:本研究使用人类癌症差异表达miRNA数据库(dbDEMC)提供的数据集对miRNA表达模式进行了全面分析。然后通过数据挖掘方法对数据集进行处理,截断值为p值1.5,以识别数据集中显著且持续上调的mirna。通过miRDIP、miRTarBase、miRPathDB和GEPIA2预测靶基因。在ShinyGO和enrichment中进行基因本体和途径富集分析。为了评估三种miRNA的诊断能力,使用CancerMIRNome对每种miRNA的ROC曲线分析结果进行鉴定。结果:这项探索性的硅分析确定了PTC中85个差异表达的mirna, hsa-miR-221-3p、hsa-miR-222-3p和hsa-miR-146b-5p在数据集中一致上调。功能富集和基于tcga的ROC分析表明,这些mirna可能在PTC中具有生物学和歧视性相关性。然而,这些发现是假设产生的,需要进一步的实验和临床验证,然后才能考虑任何诊断应用。结论:总之,我们的研究确定了hsa-miR-221-3p、hsa-miR-222-3p和hsa-miR-146b-5p作为PTC潜在诊断生物标志物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书